Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt Sells 876,000 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) Director Financial Lp Qvt sold 876,000 shares of Roivant Sciences stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the sale, the director now directly owns 22,179,358 shares of the company’s stock, valued at approximately $262,160,011.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Roivant Sciences Trading Down 1.7 %

Shares of ROIV opened at $11.57 on Friday. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.24. The company has a 50 day simple moving average of $11.49 and a two-hundred day simple moving average of $11.07. The company has a debt-to-equity ratio of 0.05, a current ratio of 27.91 and a quick ratio of 27.91. The firm has a market cap of $8.55 billion, a P/E ratio of 2.29 and a beta of 1.25.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The firm had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same quarter last year, the business posted ($0.38) earnings per share. The business’s quarterly revenue was up 155.1% compared to the same quarter last year. On average, equities analysts expect that Roivant Sciences Ltd. will post -1.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ROIV shares. Bank of America lifted their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. Finally, Piper Sandler boosted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.39.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Rubric Capital Management LP raised its stake in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 14.6% in the 1st quarter. Vanguard Group Inc. now owns 8,106,332 shares of the company’s stock valued at $85,441,000 after acquiring an additional 1,030,681 shares during the last quarter. DME Capital Management LP grew its position in Roivant Sciences by 14.8% in the second quarter. DME Capital Management LP now owns 4,810,960 shares of the company’s stock worth $50,852,000 after acquiring an additional 620,470 shares in the last quarter. Norges Bank bought a new stake in Roivant Sciences during the fourth quarter worth approximately $41,506,000. Finally, BlackBarn Capital Partners LP lifted its stake in shares of Roivant Sciences by 63.1% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock valued at $32,767,000 after purchasing an additional 1,199,406 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.